Publications

Therapeutic Areas

Modeling & Meta-Analyses

Newest to Oldest

Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?

Authors: M J Postma, D Noone, M H Rozenbaum, J A Carter, M F Botteman, E Fenwick & L P Garrison

Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea

Authors: S Ronnebaum, M Bron, D Patel, D Menno, S Bujanover, D Kratochvil, E Lucas, C Stepnowsky

An innovative approach to modelling the optimal treatment sequence for patients with relapsing–remitting Multiple Sclerosis: implementation, validation, and Impact of the decision-making approach

Authors: MA Piena, S Kroep, C Simons, E Fenwick, GH Harty, SL Wong, BA Van Hout

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis

Authors: B G Schultz, I Diakite, J A Carter, S J Snedecor, R Turpin

Does biosimilar bevacizumab offer affordable treatment options for cancer patients in the USA? A budget impact analysis from us commercial and Medicare payer perspectives

Authors: J Yang, R Liu, V Ektare, J Stephens, A Shelbaya

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

Authors: A Chatterjee, S Shapouri, BS Manzoor, A Ravelo, K Sail, V Qendri, G van de Wetering, MS Davids

Cost-effectiveness of a 12-month fixed duration of Venetoclax in combination with Obinutuzumab versus chemoimmunotherapy and other novel combinations in first-line chronic lymphocytic leukemia in Canada

Authors: A Chatterjee, G Van de Wetering, R Goeree, A M Desbois, P Manzi, B S Manzoor, C Owen, K Sail

Estimating and extrapolating survival using a state-transition modeling approach: a practical application in multiple myeloma

Authors: I Majer, S Kroep, R Maroun, C Williams, S Klijn, S Palmer

Clinical implications and cost-effectiveness analysis of Rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands

Authors: J A Spoorendonk, J-B Briere, K Bowrin, A Millier, M Coppens, S Tempelaar, B Verheggen

Cost effectiveness of Vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening heart failure event from a US Medicare perspective

Authors: Alsumali, A., Djatche, L.M., Briggs, A., Liu, R., Diakite, I., Patel, D., Wang, Y. and Lautsch, D.

View older